TransMedics Group, Inc. $TMDX Shares Acquired by Beaconlight Capital LLC

Beaconlight Capital LLC raised its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 44.8% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 42,478 shares of the company’s stock after acquiring an additional 13,134 shares during the quarter. TransMedics Group comprises about 2.2% of Beaconlight Capital LLC’s portfolio, making the stock its 14th biggest holding. Beaconlight Capital LLC’s holdings in TransMedics Group were worth $4,223,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. D.A. Davidson & CO. lifted its stake in TransMedics Group by 0.5% during the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock worth $1,865,000 after acquiring an additional 83 shares in the last quarter. Parallel Advisors LLC lifted its holdings in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the last quarter. HighPoint Advisor Group LLC grew its position in TransMedics Group by 3.1% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after buying an additional 88 shares during the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of TransMedics Group by 4.0% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after purchasing an additional 88 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its stake in shares of TransMedics Group by 2.9% during the 2nd quarter. Canada Pension Plan Investment Board now owns 3,600 shares of the company’s stock worth $482,000 after purchasing an additional 100 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at TransMedics Group

In related news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This represents a 36.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

TMDX has been the topic of several recent analyst reports. Stifel Nicolaus upped their target price on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Tuesday, June 9th. UBS Group restated a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. Finally, Oppenheimer lowered TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of “Hold” and an average price target of $134.50.

TransMedics Group Stock Up 1.6%

Shares of TransMedics Group stock opened at $72.26 on Friday. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The firm has a market cap of $2.50 billion, a P/E ratio of 16.42 and a beta of 1.89. The business has a 50-day moving average price of $71.73 and a 200 day moving average price of $102.84.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). The firm had revenue of $173.93 million for the quarter, compared to the consensus estimate of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The business’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.70 earnings per share. On average, sell-side analysts forecast that TransMedics Group, Inc. will post 1.88 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.